JP2022523047A - Cd31競合剤およびその使用 - Google Patents
Cd31競合剤およびその使用 Download PDFInfo
- Publication number
- JP2022523047A JP2022523047A JP2021543183A JP2021543183A JP2022523047A JP 2022523047 A JP2022523047 A JP 2022523047A JP 2021543183 A JP2021543183 A JP 2021543183A JP 2021543183 A JP2021543183 A JP 2021543183A JP 2022523047 A JP2022523047 A JP 2022523047A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- human
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305086 | 2019-01-23 | ||
| EP19305086.1 | 2019-01-23 | ||
| PCT/EP2020/051667 WO2020152290A1 (en) | 2019-01-23 | 2020-01-23 | Cd31 competitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523047A true JP2022523047A (ja) | 2022-04-21 |
| JP2022523047A5 JP2022523047A5 (cg-RX-API-DMAC7.html) | 2023-02-01 |
Family
ID=65409014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543183A Pending JP2022523047A (ja) | 2019-01-23 | 2020-01-23 | Cd31競合剤およびその使用 |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943505A1 (en) | 2020-07-22 | 2022-01-26 | Encefa | Cd38-binding cd31 peptides and uses thereof |
| CN117567594B (zh) * | 2023-11-30 | 2025-02-07 | 北京博奥森生物技术有限公司 | 一种模拟cd31线性分子抗原性的分支多肽制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014509837A (ja) * | 2010-12-30 | 2014-04-24 | 武田薬品工業株式会社 | 抗cd38抗体 |
| JP2018501297A (ja) * | 2014-11-04 | 2018-01-18 | グレンマーク ファーマシューティカルズ, エセ.アー. | Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法 |
| WO2018224683A1 (en) * | 2017-06-08 | 2018-12-13 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| ES2642787T3 (es) | 2005-10-21 | 2017-11-20 | Lfb Usa, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| KR101703299B1 (ko) | 2007-06-01 | 2017-02-06 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| AU2009303526B2 (en) | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| FR3003171B1 (fr) | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
-
2020
- 2020-01-23 CN CN202080023098.6A patent/CN113614107A/zh active Pending
- 2020-01-23 MX MX2021008672A patent/MX2021008672A/es unknown
- 2020-01-23 US US17/425,022 patent/US20220089765A1/en not_active Abandoned
- 2020-01-23 WO PCT/EP2020/051667 patent/WO2020152290A1/en not_active Ceased
- 2020-01-23 JP JP2021543183A patent/JP2022523047A/ja active Pending
- 2020-01-23 EP EP20701759.1A patent/EP3914616A1/en not_active Withdrawn
- 2020-01-23 AU AU2020211728A patent/AU2020211728A1/en not_active Abandoned
- 2020-01-23 CA CA3127520A patent/CA3127520A1/en active Pending
- 2020-01-23 KR KR1020217026266A patent/KR20210119448A/ko not_active Ceased
- 2020-01-23 BR BR112021014574-5A patent/BR112021014574A2/pt not_active IP Right Cessation
- 2020-01-23 SG SG11202107941TA patent/SG11202107941TA/en unknown
-
2021
- 2021-07-19 IL IL284962A patent/IL284962A/en unknown
- 2021-07-21 ZA ZA2021/05154A patent/ZA202105154B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014509837A (ja) * | 2010-12-30 | 2014-04-24 | 武田薬品工業株式会社 | 抗cd38抗体 |
| JP2018501297A (ja) * | 2014-11-04 | 2018-01-18 | グレンマーク ファーマシューティカルズ, エセ.アー. | Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法 |
| WO2018224683A1 (en) * | 2017-06-08 | 2018-12-13 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
Non-Patent Citations (1)
| Title |
|---|
| L. FRASCA, ET AL., BLOOD, vol. 107, no. 6, JPN6023052547, 2006, pages 2392 - 2399, ISSN: 0005395191 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL284962A (en) | 2021-09-30 |
| MX2021008672A (es) | 2021-11-03 |
| WO2020152290A1 (en) | 2020-07-30 |
| US20220089765A1 (en) | 2022-03-24 |
| SG11202107941TA (en) | 2021-08-30 |
| AU2020211728A1 (en) | 2021-08-12 |
| CA3127520A1 (en) | 2020-07-30 |
| BR112021014574A2 (pt) | 2021-10-05 |
| KR20210119448A (ko) | 2021-10-05 |
| EP3914616A1 (en) | 2021-12-01 |
| ZA202105154B (en) | 2023-01-25 |
| CN113614107A (zh) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12258410B2 (en) | Anti-SIRPα antibodies and methods of use thereof | |
| TW202525859A (zh) | 全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用 | |
| TWI745670B (zh) | 抗cd27抗體、其抗原結合片段及其醫藥用途 | |
| JP2021529520A (ja) | 抗sirp−ベータ1抗体及びその使用方法 | |
| EP3632932A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
| JP2023541627A (ja) | Il1rapに結合する抗体及びその使用 | |
| JP2024501539A (ja) | NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ | |
| JP7627258B2 (ja) | 抗bcma抗体、その抗原結合断片、及びそれらの医療用途 | |
| JP2023528535A (ja) | セリン413においてリン酸化されたタウを標的化する高親和性抗体 | |
| CN112424357B (zh) | 与硫酸软骨素蛋白聚糖5结合的抗体 | |
| JP2022502024A (ja) | 抗ヒトcd45rc抗体及びその使用 | |
| TWI714895B (zh) | 抗csf-1r抗體、其抗原結合片段及其醫藥用途 | |
| CN112512638A (zh) | 抗siglec-7抗体及其使用方法 | |
| TW201904999A (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| US20220089765A1 (en) | Cd31 competitors and uses thereof | |
| JP2024505987A (ja) | 抗tnfr2抗体およびその使用 | |
| EP4108683A1 (en) | Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof | |
| WO2025120583A2 (en) | CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF | |
| TW202221038A (zh) | 抗trop-2抗體、其抗原結合片段或其突變體、及其醫藥用途 | |
| CN113164601B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| CN121652273A (zh) | Cll-1抗体及其应用 | |
| KR20260005221A (ko) | Vh4-34 항원 결합 분자 | |
| HK40047611B (en) | Antibody binding to chondroitin sulfate proteoglycan-5 | |
| HK40047611A (en) | Antibody binding to chondroitin sulfate proteoglycan-5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230123 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240321 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240820 |